INCY Add to watchlist $96.74 0.76 (-0.78%) Last updated: May 30, 2026 23:25
52-Week Range
$96.74
$63.93 $96.74 $112.29

Fundamentals Overview

Incyte Corporation is in the middle of its 52-week range with attractive valuation, trading relatively flat today.

Valuation attractive

P/E 14 PEG 0 P/B 3.47 P/S 3.61

Intrinsic value (DCF)

+28.1% upside vs price

Profitability

Net margin 26.7%

Risk (Beta)

0.8 — in line vol

Earnings & growth

EPS $6.92 Rev -15.5% Profit +1.4% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 61% confidence Risk: Moderate Volatility — Beta 0.8. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +28.1% upside vs price · Analyst grade: A

Pressures (Sell):

3M vs S&P 500: -14.3%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$19.33B
P/E (TTM)
13.97
EPS (TTM)
$6.92
Dividend Yield
N/A
52-Week Range
$63.93 - $112.29
Volume vs Avg
N/A
Beta
0.8

About

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome ...
Sector: Healthcare
Headquarters: US
Employees: 2,617
IPO Date: Nov 1993
Beta: 0.8 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: A. Recent institutional grades: mixed. Current institutional positions: Buy: 11, Equal Weight: 4, Hold: 1, In Line: 1, Neutral: 1, Outperform: 1, Overweight: 8, Perform: 1, Sector Perform: 2.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $123.94; current price is $96.74. That’s a +28.1% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 13.97
DCF value (model) $123.94 (28.1% upside)
PEG (TTM) 0
P/B (TTM) 3.47
P/S (TTM) 3.61
P/FCF (TTM) 13.32
Liquidity & enterprise
Current Ratio (TTM) 3.68
Quick Ratio (TTM) 3.6
Cash Ratio (TTM) 2.32
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 26.71%
Gross margin (TTM) 92.48%
Operating margin (TTM) 27.05%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for INCY.

Analyst Sentiment at a Glance

A Sentiment Mixed
Buy 11Equal Weight 4Hold 1In Line 1Neutral 1Outperform 1Overweight 8Perform 1Sector Perform 2
2 upgrades, 2 downgrades
Price Target Consensus
Current $96.74
Median $107.00
Consensus $108.55
Low consensus $90.00
High consensus $135.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
HC Wainwright & Co. maintain Buy Buy 2026-05-21
HC Wainwright & Co. maintain Buy Buy 2026-05-04
Stifel maintain Buy Buy 2026-04-29
Oppenheimer maintain Perform Perform 2026-04-29
HC Wainwright & Co. maintain Buy Buy 2026-04-15
HC Wainwright & Co. maintain Buy Buy 2026-03-30
UBS maintain Neutral Neutral 2026-03-25
HC Wainwright & Co. maintain Buy Buy 2026-03-25
Jefferies downgrade Buy Hold 2026-03-16
HC Wainwright & Co. maintain Buy Buy 2026-03-09
Evercore ISI Group maintain In Line In Line 2026-03-05
Barclays maintain Overweight Overweight 2026-02-18
Wells Fargo maintain Equal Weight Equal Weight 2026-02-11
HC Wainwright & Co. maintain Buy Buy 2026-02-11
Stifel maintain Buy Buy 2026-02-11
RBC Capital maintain Sector Perform Sector Perform 2026-02-11
Piper Sandler maintain Overweight Overweight 2026-02-06
Barclays maintain Overweight Overweight 2026-02-04
Wells Fargo downgrade Overweight Equal Weight 2026-01-20
TD Cowen maintain Buy Buy 2026-01-13
Morgan Stanley maintain Equal Weight Equal Weight 2026-01-06
Morgan Stanley maintain Equal Weight Equal Weight 2025-12-08
Mizuho upgrade Neutral Outperform 2025-12-08
Wells Fargo maintain Overweight Overweight 2025-12-08
Barclays maintain Overweight Overweight 2025-11-24
Piper Sandler maintain Overweight Overweight 2025-11-04
Guggenheim upgrade Neutral Buy 2025-11-03
Wells Fargo maintain Overweight Overweight 2025-10-29
Barclays maintain Overweight Overweight 2025-10-29
RBC Capital maintain Sector Perform Sector Perform 2025-10-29